Patient Health Questionnaire Depression Scale (PHQ-9) for Perinatal Depression Screening
Hello,
Great insights into the discussion for this week. In the contexts of care, the PMHNP may be in an collaborative relationship with the obstetrician-gynecologist (OB/GYN) when caring for patients during the perinatal period. Having knowledge of the guidelines for depression screening for OB/GYNs allows for the PMHNP to offer more comprehensive services to patients like Natalie. The American College of Obstetricians and Gynecologists recommends that obstetrician-gynecologists and other obstetric care providers screen patients at least once during the perinatal period for depression and anxiety symptoms using a standardized, validated tool (American College of Obstetricians & Gynecologists, 2018)
What is another validated screening tool outside of the Edinburgh Postnatal Depression Scale (EPDS) that can be used to screening for perinatal depression?
References
American College of Obstetricians & Gynecologists. (2018). ACOG committee opinion No. 757: Screening for perinatal depression. (2018). Obstetrics and Gynecology, 132(5), e208–e212.
Discussion Prof Reply
Student’s Name
Professor’s Name
Institutional Affiliations
Course Name and Number
Due Date
Discussion Prof Reply
Thank you for your reply to my post. Your feedback has further expanded my perspective on depression during the perinatal period. It has enabled me to understand the essential responsibilities of PMHNPs and their close collaboration with the obstetrician-gynaecologist in ensuring patients receive optimum and desirable care. The observation about the frequency or bare minimum recommendations for screening demonstrates this mental health issue’s increased attention today. Such approaches should always occur using standardized and validated tools. Other than the Edinburgh Postnatal Depression Scale (EPDS) discussed earlier, these healthcare providers can also use the Patient Health Questionnaire Depression Scale (PHQ-9) as an alternative for perinatal depression assessment.
PHQ-9 has been in use by healthcare providers for diagnosing depression in diverse groups, including populations in their perinatal period, for years. Wang et al. (2021) report that this tool’s adaptability and applicability in diverse clinical settings, varying age groups, and health conditions make it the most used globally. Neupane et al. (2021) also make similar recognition of PHQ-9 and indicate that it has unique strengths. For instance, the author notes that, unlike EPDS, PHQ-9 has standardized cutoffs. As a result, this component makes it a robust approach for screening depression among women in their perinatal period. Despite these strengths, ...